John Stone

Principal, Co-Lead, FDA and Public Health Working Group

(202) 333-4936


Government affairs; Food, Drug and Cosmetic Act; Controlled Substances Act

Professional Experience

House Energy and Commerce Committee, Sanofi

John Stone, Principal, BGR Government Affairs, is the Co-Lead of the FDA and Public Health Working Group within BGR’s Health and Life Sciences Practice. John supports FDA-regulated clients navigate congressional and administration policy development processes that impact their products and commercial activities.

John joined the firm after spending nearly seven years with the House Energy and Commerce Committee (E&C), first as a Counsel on the Oversight and Investigations Subcommittee and then as a Senior Counsel on the Health Subcommittee primarily handling issues under the jurisdiction of the FDA.

John’s time with E&C was undoubtedly the busiest stretch of legislative action impacting the agency in decades. Working for former Chairman Fred Upton (R-Mich.) he played a leading role in developing, negotiating and ultimately passing numerous bipartisan bills, including the Drug Quality and Security Act (DQSA), the Safe and Accurate Food Labeling Act and the landmark 21st Century Cures Act (Cures)—widely considered one of the most comprehensive biomedical research and FDA reform bills ever signed into law. Under current Chairman Greg Walden (R-Ore.), John facilitated timely passage of the Food and Drug Administration Reauthorization Act (FDARA) in the midst of a very challenging political environment.

Upon John’s departure from the Committee, Rep. Upton noted that “John’s knowledge and expertise in the health care field is second to none. His contributions to our team over the years to improve the public health, particularly our 21st Century Cures effort, were immeasurable. We will miss his good nature and wise counsel.

Chairman Walden added that “John has been a valuable asset at Energy and Commerce and I’m particularly glad we had him by our side leading up to and during the critical passage of the FDA Reauthorization Act earlier this year. He brings with him a tremendous wealth of knowledge and the skills to push big tasks across the finish line. Our loss is BGR’s gain.”

Prior to joining the Committee in February 2011, John spent two years in the Washington office of Sanofi. He received his undergraduate degree from Miami University in Oxford, Ohio, and his law degree from American University in Washington, D.C.